AU2001294790A1 - Method of achieving overnight laxation and control of bowel function - Google Patents

Method of achieving overnight laxation and control of bowel function

Info

Publication number
AU2001294790A1
AU2001294790A1 AU2001294790A AU9479001A AU2001294790A1 AU 2001294790 A1 AU2001294790 A1 AU 2001294790A1 AU 2001294790 A AU2001294790 A AU 2001294790A AU 9479001 A AU9479001 A AU 9479001A AU 2001294790 A1 AU2001294790 A1 AU 2001294790A1
Authority
AU
Australia
Prior art keywords
control
overnight
bowel function
laxation
achieving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294790A
Inventor
Mark Vb. Cleveland
Russell W. Pelham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braintree Laboratories Inc
Original Assignee
Braintree Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Laboratories Inc filed Critical Braintree Laboratories Inc
Publication of AU2001294790A1 publication Critical patent/AU2001294790A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Overnight relief of constipation symptoms is achieved, and control of bowel function is enhanced by oral administration of an effective or sufficient amount of a composition comprising polyethylene glycol (PEG), preferably dispersed and or dissolved in an aqueous medium. The PEG compositions used for the present invention are preferably substantially free of ancillary electrolytes.
AU2001294790A 2000-09-28 2001-09-27 Method of achieving overnight laxation and control of bowel function Abandoned AU2001294790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/675,105 US6645481B1 (en) 2000-09-28 2000-09-28 Method of achieving overnight laxation and control of bowel function
US09675105 2000-09-28
PCT/US2001/030227 WO2002026222A2 (en) 2000-09-28 2001-09-27 Method of achieving overnight laxation and control of bowel function

Publications (1)

Publication Number Publication Date
AU2001294790A1 true AU2001294790A1 (en) 2002-04-08

Family

ID=24709076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294790A Abandoned AU2001294790A1 (en) 2000-09-28 2001-09-27 Method of achieving overnight laxation and control of bowel function

Country Status (12)

Country Link
US (1) US6645481B1 (en)
EP (1) EP1326592B1 (en)
AT (1) ATE401900T1 (en)
AU (1) AU2001294790A1 (en)
CA (1) CA2423746A1 (en)
CY (1) CY1110052T1 (en)
DE (1) DE60135001D1 (en)
DK (1) DK1326592T3 (en)
ES (1) ES2310190T3 (en)
PT (1) PT1326592E (en)
SI (1) SI1326592T1 (en)
WO (1) WO2002026222A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291324B2 (en) * 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
CA2546019A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
US7256202B2 (en) * 2003-12-31 2007-08-14 Halow George M Composition and method for treatment of hepatic encephalopathy
US20050244368A1 (en) * 2004-04-29 2005-11-03 Pashankar Dinesh S Pre-endoscopic use of polyethylene glycol compositions
WO2006118562A1 (en) * 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
US7495063B2 (en) * 2006-02-03 2009-02-24 Dow Global Technologies Inc. Reduced oligomer concentration in high purity polyalkylene glycols
WO2014144407A1 (en) 2013-03-15 2014-09-18 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
BR112016025481A2 (en) 2014-04-29 2017-08-15 Colonaryconcepts Llc Foods, Systems, Methods and Cases for Electrolyte Replacement Provision
KR102091852B1 (en) 2015-03-02 2020-03-23 코로나리콘셉츠 엘엘씨 Compounds and methods for assaying PEG metabolites and PEG degradation products

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
US6048901A (en) * 1999-04-20 2000-04-11 Braintree Laboratories, Inc. Method of reducing intestinal gas, cramping and anorectal irritation

Also Published As

Publication number Publication date
US6645481B1 (en) 2003-11-11
WO2002026222A8 (en) 2002-06-27
EP1326592B1 (en) 2008-07-23
CA2423746A1 (en) 2002-04-04
DK1326592T3 (en) 2008-11-10
SI1326592T1 (en) 2009-02-28
ES2310190T3 (en) 2009-01-01
PT1326592E (en) 2008-10-20
EP1326592A1 (en) 2003-07-16
CY1110052T1 (en) 2015-01-14
ATE401900T1 (en) 2008-08-15
DE60135001D1 (en) 2008-09-04
WO2002026222A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
CY1110052T1 (en) THE USE OF POLYETHYLENE GLYCLE (PEG) FOR CONSTRUCTION OF MEDICINAL TREATMENT
AU5371498A (en) Polymer film compositions for capsules
EP1048297A3 (en) Use of polyethylene glycol for reducing of intestinal gas, cramping and anorectal irritation
MXPA03005893A (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs.
EP1086701A3 (en) Simethicone containing laxative composition
AU2001272516A1 (en) Anti-slip protection device for a housing head for medical instruments
AU1339095A (en) Laxative compositions containing bulk fiber and dioctyl sulfosuccinate
CA2334534A1 (en) Dental restoratives
CA2390824A1 (en) Stabilized aqueous acidic antiperspirant compositions and related methods
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
WO2001068144A3 (en) Biodegradable immunomodulatory formulations and methods for use thereof
NO20021013L (en) Aqueous gelled composition comprising a block copolymer including at least one water-soluble block and a hydrophobic block
YU54301A (en) Gcsf conjugates
TR200003666T2 (en) Formoterol for the prevention, treatment of an acute case of asthma
WO2005110398A3 (en) Pharmaceutical solution formulations containing 17-aag
AU5317596A (en) Emulsified, low ph cosmetic compositions having improved stability
CA2334460A1 (en) Pharmaceutical compositions comprising alpha-adrenoceptor antagonists and muscarinic antagonists
SE0102843L (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
PL346764A1 (en) New oral formulation for 5-ht4
EP1435230A3 (en) Sunscreen compositions
WO2002034202A3 (en) Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
MY136987A (en) Ciclesonide contained pharmaceutical composition for application to mucosa
CA2428324A1 (en) Dentifrice composition comprising hydroxyethyl cellulose, an anhydrous humectant, a polyethylene glycol and an abrasive
DE60003943D1 (en) TRIMEGESTONE CONTAINING PHARMACEUTICAL COMPOSITIONS
AU2000256368A1 (en) Polysaccharide and dimethicone copolyol as emulsifier for cosmetic compositions